DDInter1891 DDInter1676
Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tucatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Tucatinib {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Tucatinib {u} may lead to a major life threatening interaction when taken with {v} Olaparib
Tucatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Tucatinib may lead to a major life threatening interaction when taken with Ribociclib
Tucatinib may lead to a major life threatening interaction when taken with Olaparib